Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, U.S.A.;
Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore, MD, U.S.A.
Anticancer Res. 2022 Apr;42(4):1867-1877. doi: 10.21873/anticanres.15663.
BACKGROUND/AIM: The addition of radiation to chemotherapy in elderly patients with primary central nervous system lymphoma (PCNSL) remains controversial. This aim of this study was to assess the trend of combined modality treatment (CMT) and compare its survival with chemotherapy alone and radiation alone in non-HIV patients.
We identified 6,537 patients who received single treatment modality, CMT, or no treatment at all between 2004 and 2015 from the National Cancer Database. Factors affecting treatment selection were investigated using a logistic regression model. Annual percentage change (APC) was calculated to assess the trend of CMT use. A propensity score weighting methodology was used to compare survival outcomes.
Only 12.8% of patients received CMT, and this proportion steadily declined between 2004 (17.7%) and 2015 (8.7%), with an APC of -6.0% (95%CI=-8.0 - -4.0, p-value <0.001) during the 12 years. Apart from classical prognostic factors (age and comorbidities), treatment selection was significantly influenced by sex, facility type, degree of urbanization, and type of insurance. CMT had improved survival [median overall survival 19.5 months (95%CI=15.7-22.8)] compared with single-modality treatment. This effect was more prominent in the first year.
Socioeconomic factors affect the selection of treatment in elderly patients with PCNSL. CMT is falling out of favor in this patient population due to the risks of neurotoxicity. Further work should focus on developing strategies that minimize toxicity and access disparities without compromising survival.
背景/目的:在老年原发性中枢神经系统淋巴瘤(PCNSL)患者中,放化疗联合治疗仍存在争议。本研究旨在评估联合治疗模式(CMT)的趋势,并与单纯化疗和单纯放疗的生存情况进行比较,研究对象为非 HIV 患者。
我们从国家癌症数据库中确定了 2004 年至 2015 年间接受单一治疗模式、CMT 或未接受任何治疗的 6537 名患者。使用逻辑回归模型探讨影响治疗选择的因素。计算年度百分比变化(APC)以评估 CMT 使用趋势。采用倾向评分加权法比较生存结果。
仅有 12.8%的患者接受 CMT,且该比例在 2004 年(17.7%)至 2015 年(8.7%)间稳步下降,12 年间的 APC 为-6.0%(95%CI=-8.0- -4.0,p<0.001)。除了经典预后因素(年龄和合并症)外,治疗选择还受到性别、医疗机构类型、城市化程度和保险类型的显著影响。CMT 可改善生存[中位总生存期 19.5 个月(95%CI=15.7-22.8)],优于单一治疗模式。这一效果在第一年更为显著。
社会经济因素影响老年 PCNSL 患者的治疗选择。由于神经毒性风险,CMT 在该患者人群中逐渐不受青睐。进一步的工作应集中于制定策略,在不影响生存的情况下最大限度地降低毒性和获取差异。